Skip to main content

Advertisement

Log in

Chronic Daily Headache: Mechanisms and Principles of Management

  • Other Pain (N Vadivelu and A Kaye, Section Editors)
  • Published:
Current Pain and Headache Reports Aims and scope Submit manuscript

Abstract

Primary headache is a common malady that is often under-recognized and frequently inadequately managed in spite of the fact that it affects up to 95 % of the population in a lifetime. Many forms of headache, including episodic tension and migraine headaches, if properly diagnosed, are reasonably amenable to treatment, but a smaller, though not insignificant, percent of the population suffer daily from a chronic, intractable form of headache that destroys one’s productivity and quality of life. These patients are frequently seen in neurological practices at a point when treatment options are limited and largely ineffective. In the following review, we will discuss mechanisms drawn from recent studies that address the transition from acute to chronic pain that may apply to the transformation from episodic to chronic daily headaches which may offer opportunities for preempting headache transformation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance, •• Of major importance

  1. Linet MS, Stewart WF, Celentano DD, Ziegler D, Sprecher M. An epidemiologic study of headache among adolescents and young adults. JAMA. 1989;261:2211–6.

    Article  PubMed  CAS  Google Scholar 

  2. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646–57.

    Article  PubMed  CAS  Google Scholar 

  3. Silberstein SD, Lipton RB. Chronic daily headache, including transformed migraine, chronic tension-type headache and medication overuse. In: Silberstein SD, Lipton RB, Dalessio DJ, editors. Wolff’s headache and other head pain. 4th ed. New York: Oxford University Press; 2001. p. 247–82.

    Google Scholar 

  4. Lipton RB. Tracing transformation: chronic migration classification, progression, and epidemiology. Neurology. 2009;72:S3–7.

    Article  PubMed  Google Scholar 

  5. Raskin NH. Approach to the patient with migraine. Hosp Pract. 1996;31:93–104.

    CAS  Google Scholar 

  6. Evans RW. A rational approach to the management of chronic migraine. Headache. 2013;53:168–76. This is an excellent review of current clinical approaches to treating chronic headaches in terms of medications, office procedures, surgical procedures and non-pharmacologic therapies.

    Article  PubMed  Google Scholar 

  7. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American headache society evidence assessment of migraine pharmacotherapies. Headache. 2015;55:3–20.

    Article  PubMed  Google Scholar 

  8. Afridi SK, Shields KG, Bhola R, Goadsby PJ. Greater occipital nerve injection in primary headache syndromes: prolonged effects from a single injection. Pain. 2006;122:126–9.

    Article  PubMed  CAS  Google Scholar 

  9. Naumann M, So Y, Argoff CE, Childers MK, Dykstra DD, Gronseth GS, et al. Therapeutics and technology assessment subcommittee of the American Academy of Neurology. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology. 2008;70:1707–14.

    Article  PubMed  CAS  Google Scholar 

  10. Young WB, Marmura M, Ashkenazi A, Evans RW. Expert opinion: greater occipital nerve and other anesthetic injections for primary headache disorders. Headache. 2008;48:1122–5.

    Article  PubMed  Google Scholar 

  11. Saper JR, Silberstein SD, Lake III AE, Winters ME. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache. 1994;34:497–502.

    Article  PubMed  CAS  Google Scholar 

  12. Krymchantowski AV, Silva MT, Barbosa JS, Alves LA. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. Headache. 2002;42:510–4.

    Article  PubMed  Google Scholar 

  13. Tarlaci S. Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders. Clin Neuropharmacol. 2009;32:254–8.

    Article  PubMed  CAS  Google Scholar 

  14. Hain TC, Cherchi M. Migraine headache: prevention. Dizziness-and-balance.com. 2015; http://www.dizziness-and-balance.com/disorders/central/migraine/migraine%20prevention.html.

  15. Mathew NT, Ali S. Valproate in the treatment of persistent chronic daily headache. An open label study. Headache. 1991;31:71–4.

    Article  PubMed  CAS  Google Scholar 

  16. Spira PJ, Beran RG. Australian gabapentin chronic daily headache group. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology. 2003;61:1753–9.

    Article  PubMed  CAS  Google Scholar 

  17. Rapoport AM, Sheftell FD, Tepper SJ, Bigal M. Levetiracetam in the preventive treatment of transformed migraine. Curr Ther Res. 2005;66:212–21.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  18. Silberstein SD, Loder E, Forde G, Papadopoulos G, Fairclough D, Greenberg S. The impact of migraine on daily activities: effect of topiramate compared with placebo. Curr Med Res Opin. 2006;22:1021–9.

    Article  PubMed  CAS  Google Scholar 

  19. Silberstein SD, Lipton RB, Dodick DW, Topiramate Chronic Migraine Study Group, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47:170–80.

    Article  PubMed  Google Scholar 

  20. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. TOPMAT-MIG-201(TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814–23.

    Article  PubMed  Google Scholar 

  21. Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev. 2004;2:CD003225.

    PubMed  Google Scholar 

  22. Silberstein SD. Preventive treatment of migraine. Trends Pharmacol Sci. 2006;27:410–5.

    Article  PubMed  CAS  Google Scholar 

  23. Nandha R, Singh H. Renin angiotensin system: a novel target for migraine prophylaxis. Indian J Pharm. 2012;44:157–60.

    Article  CAS  Google Scholar 

  24. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Quality standards subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337–45. This report provides a comprehensive analysis of published studies from 1999 to 2009 that looked at class I and II articles that listed level A evidence of efficacy for medications used for the prevention of episodic migraine. Guidelines are provided for the use of medications that ideally decrease the frequency and severity of migraine attack, thereby reducing medication overuse and the potential transition to chronic headaches.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  25. Saper JR, Lake III AE, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache. 2002;42:470–82.

    Article  PubMed  Google Scholar 

  26. Tepper SJ, Bigal M, Rapoport A, Sheftell F. Alternative therapies: evidence based evaluation in migraine. Headache Care. 2006;3:57–64.

    Article  Google Scholar 

  27. Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1346–53.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  28. Garza I, Schwedt TJ. Diagnosis and management of chronic daily headache. Semin Neurol. 2010;30:154–66.

    Article  PubMed  Google Scholar 

  29. Bigal ME, Lipton RB. Clinical course in migraine: conceptualizing migraine transformation. Neurology. 2008;71:848–55.

    Article  PubMed  Google Scholar 

  30. Kandasamy R, Price TJ. The pharmacology of nociceptor priming. In: Shaible H-G, editor. Pain Control, Handbook of Exper Pharmacol. 2015;227:15–37.

  31. Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB. Transformed migraine and medication overuse in a tertiary headache centre—clinical characteristics and treatment outcomes. Cephalalgia. 2004;24:483–90.

    Article  PubMed  CAS  Google Scholar 

  32. Johnson JL, Hutchinson MR, Williams DB. Medication-overuse headache and opioid-induced hyperalgesia: a review of mechanisms, a neuroimmune hypothesis and a novel approach to treatment. Cephalalgia. 2012;33:52–64.

    Article  PubMed  Google Scholar 

  33. Hutchinson MR, Bland ST, Johnson KW, Rice KC, Maier SF, Watkins LR. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. Sci World J. 2007;7:98–111.

    Article  Google Scholar 

  34. Hutchinson MR, Northcutt AL, Chao LW, Kearney JJ, Zhang Y, Berkelhammer DL, et al. Minocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesia. Brain Behav Immun. 2008;22:1248–56.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  35. Meng ID, Cao L. From migraine to chronic daily headache: the biological basis of headache transformation. Headache. 2007;47:1251–8.

    Article  PubMed  Google Scholar 

  36. Milligan E, Watkins L. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci. 2009;10:23–36.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  37. Watkins LR, Hutchinson MR, Rice KC, Maier SF. The “toll” of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci. 2009;30:581–91.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  38. Thalakoti S, Patil VV, Damodaram S, Vause CV, Langford LE, Freeman SE, et al. Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache. 2007;47:1008–23.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Ollat H, Cesaro P. Pharmacology of neuropathic pain. Clin Neuropharmacol. 1995;18:391–404.

    Article  PubMed  CAS  Google Scholar 

  40. Kandel ER. The molecular biology of memory storage: a dialog between genes and synapses. Biosci Rep. 2004;24:475–522.

    Article  PubMed  CAS  Google Scholar 

  41. Tao YX. AMPA receptor trafficking in inflammation-induced dorsal horn central sensitization. Neurosci Bull. 2012;28:111–20.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  42. Price TJ, Ghosh S. ZIPping to pain relief: the role (or not) of PKMζ in chronic pain. Mol Pain. 2013;9:6.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  43. Price TJ, Inyang KE. Commonalities between pain and memory mechanisms and their meaning for understanding chronic pain. Prog Mol Biol Transl Sci. 2015;131:409–34.

    Article  PubMed Central  PubMed  Google Scholar 

  44. Ledeboer A, Sloane EM, Milligan ED, Frank MG, Mahony JH, Maier SF, et al. Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain. 2005;115:71–83.

    Article  PubMed  CAS  Google Scholar 

  45. Hutchinson MR, Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX, et al. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun. 2010;24:83–95.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  46. Ledeboer A, Liu T, Shumilla JA, Mahoney JH, Vijay S, Gross MI, et al. The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glia Biol. 2006;2:279–91.

    Article  PubMed  Google Scholar 

  47. Rolan P, Hutchinson M, Johnson K. Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease. Expert Opin Pharmacother. 2009;10:2897–904.

    Article  PubMed  CAS  Google Scholar 

  48. Barkhof F, Hulst HE, Drulovic J, Uitdehaag BM, Matsuda K, Landin R. MN166-001 investigators. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology. 2010;74:1033–40.

    Article  PubMed  CAS  Google Scholar 

  49. Volfe Z, Dvilansky A, Nathan I. Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients. Int J Clin Pharmacol Res. 1985;5:243–6.

    PubMed  CAS  Google Scholar 

  50. Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag. 2008;4:245–59.

    PubMed Central  PubMed  CAS  Google Scholar 

  51. Baron EP. Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it’s been …. Headache. 2015;55:885–916.

    Article  PubMed  Google Scholar 

  52. Watkins L, Glia MS. A novel drug discovery target for clinical pain. Nat Rev Drug Discov. 2003;2:973–85.

    Article  PubMed  CAS  Google Scholar 

  53. Vanast WJ. New daily persistent headaches: definition of a benign syndrome. Headache. 1986;26:317.

    Google Scholar 

  54. Diaz-Mitoma F, Vanast WJ, Tyrrell DL. Increased frequency of Epstein-Barr virus excretion in patients with new daily persistent headaches. Lancet. 1987;1:411–5.

    Article  PubMed  CAS  Google Scholar 

  55. Hamada T, Ohshima K, Ide Y, Sakato S, Takamori M. A case of new daily persistent headache with elevated antibodies to Epstein-Barr virus. Jpn J Med. 1991;30:161–3.

    Article  PubMed  CAS  Google Scholar 

  56. Santoni JR, Santoni-Williams CJ. Headache and painful lymphadenopathy in extracranial or systemic infection: etiology of new daily persistent headaches. Intern Med. 1993;32:530–2.

    Article  PubMed  CAS  Google Scholar 

  57. Li D, Rozen TD. The clinical characteristics of new daily persistent headache. Cephalalgia. 2002;22:66–9.

    Article  PubMed  CAS  Google Scholar 

  58. Takase Y, Nakano M, Tatsumi C, Matsuyama T. Clinical features, effectiveness of drug-based treatment, and prognosis of new daily persistent headache (NDPH): 30 cases in Japan. Cephalalgia. 2004;24:955–9.

    Article  PubMed  CAS  Google Scholar 

  59. Rozen TD. New daily persistent headache. Curr Pain Headache Rep. 2003;7:218–23.

    Article  PubMed  Google Scholar 

  60. Rozen TD. New daily persistent headache. In: Goadsby PJ, Dodick DW, editors. Chronic daily headache for clinicians. 1st ed. Hamilton, Ontario: BC Decker Inc; 2005. p. 209–15.

    Google Scholar 

  61. Lipton RB. Risk factors for and management of medication-over use headache. Continuum (Minneap Minn). 2015;21:1118–31. This review compares MOH (a secondary headache disorder) to chronic daily headache, and provides guidelines to help the practitioner manage and reduce the risk of medication-overuse headache and limit the development of chronic daily headache.

    Google Scholar 

  62. Krusz JC, Scott V, Belanger J. Intravenous propofol: unique effectiveness in treating intractable migraine. Headache. 2000;40:224–30.

    Article  PubMed  CAS  Google Scholar 

  63. Krusz JC. Intravenous treatment of chronic daily headaches in the outpatient headache clinic. Curr Pain Headache Rep. 2006;10:47–53.

    Article  PubMed  Google Scholar 

  64. Gould III HJ. Management of painful neuropathies. Curr Treat Options Neurol. 2007;9:75–84.

    Article  PubMed  Google Scholar 

  65. Obermann M, Katsarava Z. Management of medication-overuse headache. Expert Rev Neurother. 2007;7:1145–55.

    Article  PubMed  CAS  Google Scholar 

  66. Mathew NT, Kurman R, Perez F. Drug induced refractory headache—clinical features and management. Headache. 1990;30:634–8.

    Article  PubMed  CAS  Google Scholar 

  67. Biondi DM. Is migraine a neuropathic pain syndrome? Curr Pain Headache Rep. 2006;10:167–78.

    Article  PubMed  Google Scholar 

  68. Woolf CJ, Walters ET. Common patterns of plasticity contributing to nociceptive sensitization in mammals and Aplysia. Trends Neurosci. 1991;14:74–8.

    Article  PubMed  CAS  Google Scholar 

  69. Bliss TV, Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol. 1973;232:331–56.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  70. Cooper JR, Bloom FE, Roth RH. The biochemical basis of neuropharmacology. 6th ed. New York: Oxford University Press; 1991. p. 428–46.

    Google Scholar 

  71. Hebb DO. The organization of behavior. NY: Wiley (Interscience); 1949.

    Google Scholar 

  72. Ji RR, Kohno T, Moore KA, Woolf CJ. Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci. 2003;26:696–705.

    Article  PubMed  CAS  Google Scholar 

  73. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009;10:895–926.

    Article  PubMed Central  PubMed  Google Scholar 

  74. Woolf CJ. Central sensitization: uncovering the relation between pain and plasticity. Anesthesiology. 2007;106:864–7.

    Article  PubMed  Google Scholar 

  75. Reichling DB, Levine JD. Critical role of nociceptor plasticity in chronic pain. Trends Neurosci. 2009;32:611–8.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  76. Pavlov IP. Conditional reflexes. London: Oxford University Press; 1927.

    Google Scholar 

  77. Windholz G. The discovery of the principles of reinforcement, extinction, generalization, and differentiation of conditional reflexes in Pavlov’s laboratories. Pavlov J Biol Sci. 1989;24:35–42.

    PubMed  CAS  Google Scholar 

  78. Joseph EK, Levine JD. Hyperalgesic priming is restricted to isolectin B4-positive nociceptors. Neuroscience. 2010;169:431–5.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  79. Khasar SG, Burkham J, Dina OA, Brown AS, Bogen O, Alessandri-Haber N, et al. Stress induces a switch of intracellular signaling in sensory neurons in a model of generalized pain. J Neurosci. 2008;28:5721–30.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  80. Joseph EK, Reichling DB, Levine JD. Shared mechanisms for opioid tolerance and a transition to chronic pain. J Neurosci. 2010;30:4660–6.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  81. Melemedjian OK, Asiedu MN, Tillu DV, Peebles KA, Yan J, Ertz N, et al. IL-6- and NGF-induced rapid control of protein synthesis and nociceptive plasticity via convergent signaling to the eIF4F complex. J Neurosci. 2010;30:15113–23.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  82. Melemedjian OK, Asiedu MN, Tillu DV, Sanoja R, Yan J, Lark A, et al. Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain. Mol Pain. 2011;7:70.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  83. Melemedjian OK, Tillu DV, Asiedu MN, Mandell EK, Moy JK, Blute VM, et al. BDNF regulates atypical PKC at spinal synapses to initiate and maintain a centralized chronic pain state. Mol Pain. 2013;9:12.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  84. Price TJ, Dussor GAMPK. An emerging target for modification of injury-induced pain plasticity. Neurosci Lett. 2013;557(Pt A):9–18.

    Article  PubMed  CAS  Google Scholar 

  85. Russe OQ, Möser CV, Kynast KL, King TS, Stephan H, Geisslinger G, et al. Activation of the AMP-activated protein kinase reduces inflammatory nociception. J Pain. 2013;14:1330–40.

    Article  PubMed  CAS  Google Scholar 

  86. Bassell GJ, Warren ST. Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron. 2008;60:201–14.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  87. Ferrari LF, Bogen O, Levine JD. Role of nociceptor αCaMKII in transition from acute to chronic pain (hyperalgesic priming) in male and female rats. J Neurosci. 2013;33:11002–11.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  88. Rivat C, Bollag L, Richebé P. Mechanisms of regional anaesthesia protection against hyperalgesia and pain chronicization. Curr Opin Anaesthesiol. 2013;26:621–5.

    Article  PubMed  CAS  Google Scholar 

  89. Ashkenazi A, Benlifer A, Korenblit J, Silberstein SD. Zonisamide for migraine prophylaxis in refractory patients. Cephalalgia. 2006;26:1199–202.

    Article  PubMed  CAS  Google Scholar 

  90. Spengos K, Theleritis C, Paparrigopoulos T. Memantine and NMDA antagonism for chronic migraine: a potentially novel therapeutic approach? Headache. 2008;48:284–6.

    Article  PubMed  Google Scholar 

  91. Bigal M, Rapoport A, Sheftell F, Tepper D, Tepper S. Memantine in the preventive treatment of refractory migraine. Headache. 2008;48:1337–42.

    Article  PubMed  Google Scholar 

  92. Wang ZJ, Wang LX. Phosphorylation: a molecular switch in opioid tolerance. Life Sci. 2006;79:1681–91.

    Article  PubMed  CAS  Google Scholar 

  93. Cavallo JS, Hamilton BN, Farley J. Behavioral and neural bases of extinction learning in Hermissenda. Front Behav Neurosci. 2014;8(277):1–17.

    Google Scholar 

  94. Cavallo JS, Hamilton BN, Farley J. In vitro extinction learning in Hermissenda: involvement of conditioned inhibition molecules. Front Behav Neurosci. 2014;8(354):1–24.

    Google Scholar 

  95. Hüllemann P, Shao YQ, Manthey G, Binder A, Baron R. Central habituation and distraction alter C-fibre-mediated laser-evoked potential amplitudes. Eur J Pain. 2015. doi:10.1002/ejp.735.

  96. Shealy CN. Guided imagery, mindful meditation, and hypnosis for pain management. Pract Pain Manage. 2015;15:29–34.

    Google Scholar 

  97. Trevelyan EG, Turner WA, Robinson N. Acupuncture for the treatment of phantom limb pain in lower limb amputees: study protocol for a randomized controlled feasibility trial. Trials. 2015;16(158):1–8.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Harry J. Gould III.

Ethics declarations

Conflict of Interest

Amy W. Voigt and Harry J. Gould III declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Other Pain

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Voigt, A.W., Gould, H.J. Chronic Daily Headache: Mechanisms and Principles of Management. Curr Pain Headache Rep 20, 10 (2016). https://doi.org/10.1007/s11916-016-0542-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11916-016-0542-3

Keywords

Navigation